Efficacy and Safety of Primary Radiotherapy in Combination with EGFR-TKIs for Non-Small Cell Lung Cancer Harboring EGFR Mutation  

作　　者：Dongxu Ao Meng Wang Jinyuan Xie Yang Zhang Xinran Zhang Ya Shu Chenshi Lin Qingqing Ye Dongxu Ao;Meng Wang;Jinyuan Xie;Yang Zhang;Xinran Zhang;Ya Shu;Chenshi Lin;Qingqing Ye(Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China;Department of Joint Surgery and Sports Medicine, Jingmen Central Hospital, Jingmen, China;Department of Breast Surgery, The First Affiliated Hospital of Yangtze University, Jingzhou, China)

机构地区：[1]Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China [2]Department of Joint Surgery and Sports Medicine, Jingmen Central Hospital, Jingmen, China [3]Department of Breast Surgery, The First Affiliated Hospital of Yangtze University, Jingzhou, China

出　　处：《Journal of Biosciences and Medicines》2024年第9期142-154,共13页生物科学与医学（英文）

摘　　要：Objective: To evaluate the efficacy and safety of EGFR-TKI with the radiotherapy in EGFR mutant metastatic NSCLC. Methods: Retrospective analysis of 72 patients with stage IV lung cancer with EGFR-sensitive mutation. Patients in the A group were treated with the first-generation EGFR-TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) combined with radiotherapy for primary tumors (34 cases). The B group was treated with the first-generation EGFR-TKI alone until the disease progressed (38 cases). PFS, OS, pulmonary infection and hematological toxicity during treatment were commented in both groups. Results: The objective remission rate was 47.1% (16/34) in the A group and 21.1% (8/38) in the B group. There was a significant difference between the two groups. There was no significant difference in hematological toxicity between the A group and the B group. There were 10 patients (29.4%) with degree II pulmonary infection in the A group and 3 patients (7.9%) in the B group. The difference between the two groups was statistically significant, suggesting that the incidence of pneumonia in the A group was higher than that in the B group. The median PFS (Progression-Free Survival)) and OS (Overall Survival) of the A group were significantly longer than those of the B group (16.5 months vs 9 months) and the median OS (36 months vs 19 months). The PFS and OS in the A group were significantly longer than those in the B group. Conclusion: EGFR-TKI combined with primary radiotherapy can significantly prolong the drug resistance time of EGFR mutant metastatic NSCLC.Objective: To evaluate the efficacy and safety of EGFR-TKI with the radiotherapy in EGFR mutant metastatic NSCLC. Methods: Retrospective analysis of 72 patients with stage IV lung cancer with EGFR-sensitive mutation. Patients in the A group were treated with the first-generation EGFR-TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) combined with radiotherapy for primary tumors (34 cases). The B group was treated with the first-generation EGFR-TKI alone until the disease progressed (38 cases). PFS, OS, pulmonary infection and hematological toxicity during treatment were commented in both groups. Results: The objective remission rate was 47.1% (16/34) in the A group and 21.1% (8/38) in the B group. There was a significant difference between the two groups. There was no significant difference in hematological toxicity between the A group and the B group. There were 10 patients (29.4%) with degree II pulmonary infection in the A group and 3 patients (7.9%) in the B group. The difference between the two groups was statistically significant, suggesting that the incidence of pneumonia in the A group was higher than that in the B group. The median PFS (Progression-Free Survival)) and OS (Overall Survival) of the A group were significantly longer than those of the B group (16.5 months vs 9 months) and the median OS (36 months vs 19 months). The PFS and OS in the A group were significantly longer than those in the B group. Conclusion: EGFR-TKI combined with primary radiotherapy can significantly prolong the drug resistance time of EGFR mutant metastatic NSCLC.

关 键 词：Non-Small Cell Lung Cancer Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor RADIOTHERAPY 

分 类 号：R73[医药卫生—肿瘤]